Douglas A Rubinson
Overview
Explore the profile of Douglas A Rubinson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
3343
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh H, Lowder K, Kapner K, Kelly R, Zheng H, McCleary N, et al.
Nat Commun
. 2024 Aug;
15(1):6833.
PMID: 39122726
Preclinical studies suggest that simultaneous HER2/VEGF blockade may have cooperative effects in gastroesophageal adenocarcinomas. In a single-arm investigator initiated clinical trial for patients with untreated advanced HER2+ gastroesophageal adenocarcinoma, bevacizumab...
2.
Oberstein P, Dias Costa A, Kawaler E, Cardot-Ruffino V, Rahma O, Beri N, et al.
Cancer Immunol Res
. 2024 Jul;
12(9):1221-1235.
PMID: 38990554
Innate inflammation promotes tumor development, although the role of innate inflammatory cytokines in established human tumors is unclear. Herein, we report clinical and translational results from a phase Ib trial...
3.
DeRidder L, Hare K, Lopes A, Jenkins J, Fitzgerald N, MacPherson E, et al.
Med
. 2024 Apr;
5(7):780-796.e10.
PMID: 38663403
Background: Dosing of chemotherapies is often calculated according to the weight and/or height of the patient or equations derived from these, such as body surface area (BSA). Such calculations fail...
4.
Singh H, Sahgal P, Kapner K, Corsello S, Gupta H, Gujrathi R, et al.
Clin Cancer Res
. 2024 Feb;
30(8):1669-1684.
PMID: 38345769
Purpose: ERBB2-amplified colorectal cancer is a distinct molecular subtype with expanding treatments. Implications of concurrent oncogenic RAS/RAF alterations are not known. Experimental Design: Dana-Farber and Foundation Medicine Inc. Colorectal cancer...
5.
Huffman B, Singh H, Ali L, Horick N, Wang S, Hoffman M, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38272561
Background: Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous cell carcinoma and biomarkers predictive of response are greatly needed....
6.
Rubinson D, Tanaka N, Fece de la Cruz F, Kapner K, Rosenthal M, Norden B, et al.
Cancer Discov
. 2024 Jan;
14(5):727-736.
PMID: 38236605
Significance: These studies demonstrate that certain KRASG12C inhibitors effectively target all RASG12C mutations and that sotorasib specifically is a potent NRASG12C inhibitor capable of driving clinical responses. These findings have...
7.
Ben-Ami R, Wang Q, Zhang J, Supplee J, Fahrmann J, Lehmann-Werman R, et al.
Gut
. 2023 Dec;
73(4):639-648.
PMID: 38123998
Objective: Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed at an advanced stage. Liquid biopsy approaches may facilitate detection of early stage PDAC when curative treatments can be employed. Design: To...
8.
Huffman B, Feng H, Parmar K, Wang J, Kapner K, Kochupurakkal B, et al.
Clin Cancer Res
. 2023 Oct;
29(24):5047-5056.
PMID: 37819936
Purpose: Combining gemcitabine with CHK1 inhibition has shown promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC). Here, we report the findings from a phase I expansion cohort study (NCT02632448)...
9.
Barzi A, Kim A, Liang C, West H, Wong D, Wright C, et al.
J Pers Med
. 2023 Sep;
13(9).
PMID: 37763145
Background: Pancreatic adenocarcinoma is an aggressive disease and the delivery of comprehensive care to individuals with this cancer is critical to achieve appropriate outcomes. The identification of gaps in care...
10.
Singh H, Keller R, Kapner K, Dilly J, Raghavan S, Yuan C, et al.
Clin Cancer Res
. 2023 Jul;
29(22):4627-4643.
PMID: 37463056
Purpose: Approximately 8% to 10% of pancreatic ductal adenocarcinomas (PDAC) do not harbor mutations in KRAS. Understanding the unique molecular and clinical features of this subset of pancreatic cancer is...